Objective
Fatty Liver disease (FLD) is a widespread disease which can often progress to Nonalcoholic steatohepatitis, cirrhosis and liver cancer. At present FLD disease affects a huge perportion of the population and prompt treatment will be of major health benefits to the general population. We have developed a specific therapeutic targeting a microRNA we and others have shown to be involved in the pathogenesis of FLD. This therapeutic agent can dramatically reduce FLD in a mouse model. We would like to extend the pre-clinical studies in order to encourage interest of a pharmaceutical company who will license the technology and pursue clinical trials.
Fields of science
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
THE HEBREW UNIVERSITY OF JERUSALEM
Net EU contribution
€ 149 800,00
Address
EDMOND J SAFRA CAMPUS GIVAT RAM
91904 Jerusalem
Israel
91904 Jerusalem
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 149 800,00